MetaCap

Capricor Therapeutics (CAPR) vs Lyell Immunopharma (LYEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Capricor Therapeutics (CAPR) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 32.0% versus a loss of 27.9%. Over five years, CAPR leads with a +122.6% price change compared with -92.6% for LYEL. Lyell Immunopharma is the larger company by market cap ($441.8 million vs $441.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAPR+32.00%LYEL-27.86%
+543%+227%-90%
Nov 21, 20251 yearNov 20, 2026
CAPR+127.93%LYEL-93.62%
+1012%+431%-149%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAPR versus LYEL key metrics
MetricCAPRLYEL
Share price$7.59$13.80
Market cap$441.30M$441.82M
1-day change+0.80%+1.62%
YTD return-73.70%-55.17%
1-year return+32.00%-27.86%
5-year return+122.58%-92.59%
EPS (TTM)$-2.65$-12.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$36.00K
Revenue growth (YoY)-100.00%-40.98%
Net income (latest FY)$-105.04M$-274.45M
Operating margin—-748344.44%
Net margin—-762355.56%
52-week high$40.37$45.00
52-week low$2.96$7.20
Distance from 52-week high-81.20%-69.33%
Analyst consensusbuybuy
Avg. price target upside+259.03%+172.68%
Average volume4.73M174.76K
Shares outstanding58.14M32.02M
Employees231161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAPR has outperformed LYEL by 59.9 percentage points over the past year.
  • Lyell Immunopharma grew revenue faster in its latest fiscal year (-40.98% vs -100.00%).

About Capricor Therapeutics

CAPR stock →

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees

About Lyell Immunopharma

LYEL stock →

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

CAPR vs LYEL FAQ

Which is bigger, Capricor Therapeutics or Lyell Immunopharma?

Lyell Immunopharma (LYEL) is larger, with a market capitalization of $441.82M compared with $441.30M for Capricor Therapeutics (CAPR).

Which stock has performed better over the past year, CAPR or LYEL?

CAPR returned +32.00% over the past 12 months, compared with -27.86% for LYEL (price return, excluding dividends). Past performance does not predict future results.

Are Capricor Therapeutics and Lyell Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons